Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$10.39
-1.0%
$10.40
$3.85
$12.43
$1.58B1.831.65 million shs1.44 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$9.94
-1.1%
$8.73
$6.19
$10.30
$6.83B0.551.05 million shs796,127 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$35.17
-1.9%
$33.69
$27.12
$60.90
$2.11B2.41965,940 shs624,000 shs
10x Genomics stock logo
TXG
10x Genomics
$12.15
-2.4%
$10.60
$6.78
$24.76
$1.50B2.032.72 million shs1.89 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
0.00%-12.10%-0.76%+41.75%+138.85%
Grifols, S.A. stock logo
GRFS
Grifols
0.00%+2.05%+14.25%+40.40%+23.33%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-7.52%-2.01%-4.43%-37.44%
10x Genomics stock logo
TXG
10x Genomics
0.00%-5.08%+11.78%+61.78%-38.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.9641 of 5 stars
1.41.00.04.23.22.50.6
Grifols, S.A. stock logo
GRFS
Grifols
3.5325 of 5 stars
1.55.00.00.02.50.05.0
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.3086 of 5 stars
3.45.00.04.42.20.80.6
10x Genomics stock logo
TXG
10x Genomics
4.4403 of 5 stars
3.24.00.04.82.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.86
Moderate Buy$10.571.75% Upside
Grifols, S.A. stock logo
GRFS
Grifols
3.00
Buy$10.303.62% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4043.30% Upside
10x Genomics stock logo
TXG
10x Genomics
2.46
Hold$14.1316.26% Upside

Current Analyst Ratings Breakdown

Latest ADPT, TWST, TXG, and GRFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/12/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/27/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/26/2025
10x Genomics stock logo
TXG
10x Genomics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.00
6/24/2025
10x Genomics stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$12.00 ➝ $13.00
6/18/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/17/2025
Grifols, S.A. stock logo
GRFS
Grifols
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.60 ➝ $10.30
6/11/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/24/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/19/2025
10x Genomics stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $18.00
5/15/2025
10x Genomics stock logo
TXG
10x Genomics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$14.00 ➝ $14.00
5/13/2025
10x Genomics stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$178.96M8.82N/AN/A$1.37 per share7.58
Grifols, S.A. stock logo
GRFS
Grifols
$7.81B0.88$0.94 per share10.62$13.55 per share0.73
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.73N/AN/A$8.07 per share4.36
10x Genomics stock logo
TXG
10x Genomics
$624.66M2.40N/AN/A$5.81 per share2.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%8/5/2025 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$169.80M$1.178.509.470.36N/AN/AN/A7/29/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)
10x Genomics stock logo
TXG
10x Genomics
-$182.63M-$1.30N/AN/AN/A-25.14%-23.22%-18.02%8/7/2025 (Estimated)

Latest ADPT, TWST, TXG, and GRFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.35N/AN/AN/A$139.36 millionN/A
8/5/2025Q2 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.24N/AN/AN/AN/AN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
7/29/2025Q2 2025
Grifols, S.A. stock logo
GRFS
Grifols
$0.2221N/AN/AN/A$1.92 billionN/A
5/8/2025Q1 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.45-$0.36+$0.09-$0.28$131.91 million$154.88 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
5/1/2025Q1 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.92
2.82
Grifols, S.A. stock logo
GRFS
Grifols
1.13
2.60
0.97
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
10x Genomics stock logo
TXG
10x Genomics
N/A
5.37
4.68

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
6.40%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
10x Genomics stock logo
TXG
10x Genomics
9.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790151.92 million142.19 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
23,822687.55 million686.25 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240123.13 million111.57 millionOptionable

Recent News About These Companies

10x Genomics: Stuck In Neutral
10x Genomics Settles Patent Dispute With Bruker

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$10.39 -0.11 (-1.05%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.28 -0.11 (-1.01%)
As of 07/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Grifols stock logo

Grifols NASDAQ:GRFS

$9.94 -0.11 (-1.09%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$9.98 +0.04 (+0.45%)
As of 07/18/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$35.17 -0.68 (-1.90%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$35.92 +0.74 (+2.12%)
As of 07/18/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$12.15 -0.30 (-2.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$12.14 -0.01 (-0.08%)
As of 07/18/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.